Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.56 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25355590 | 0.85 | ANPEP (0.55) | ANPEPENPEPFOLH1 | |
| SCHEMBL25355588 | 0.85 | ANPEP (0.55) | ANPEPENPEPFOLH1 | |
| SCHEMBL16620907 | 0.85 | ANPEP (0.55) | ANPEPENPEPFOLH1 | |
| SCHEMBL371526 | 0.82 | FOLH1 (0.70) | ANPEPENPEPFOLH1CYP2D6CYP2C9 | |
| SCHEMBL28839142 | 0.81 | ANPEP (0.51) | ANPEPENPEPFOLH1CYP2D6CYP2C9 | |
| SCHEMBL848969 | 0.81 | FOLH1 (0.56) | ANPEPENPEPFOLH1 | |
| SCHEMBL27698939 | 0.81 | FOLH1 (0.51) | ANPEPENPEPFOLH1 | |
| SCHEMBL6277023 | 0.81 | FOLH1 (0.57) | ANPEPENPEPFOLH1 | |
| SCHEMBL4396931 | 0.81 | FOLH1 (0.51) | ANPEPENPEPFOLH1 | |
| SCHEMBL9116167 | 0.80 | ANPEP (0.52) | ANPEPENPEPFOLH1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972589-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | Merck Sharp & Dohme Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020236690-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-11-26 | — | — | WO | disclosed |